TARA

Protara Therapeutics Inc

TARA.US protaratx.com
Healthcare · Biotechnology
3.82
+0.03 (+0.79%)
USD · NASDAQ
52-week range
3.02
7.82
Trading at 17% of the 52-week range
Market Cap
225.74M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
2.73
Div. Yield
N/A
% Institutions
78.38%
% Insiders
2.30%

1 Year

+19.4%

3 Year

+80.2%

10 Year

-98.9%
Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Company Information

▼
Company Name
Protara Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US74365U1079
CIK: 0001359931
CUSIP: 04300J107
Currency: USD
Full Time Employees: 46
Phone: 646 844 0337
Website: protaratx.com
Fiscal Year End: December
IPO Date: Oct 22, 2014
Description:

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Address:

345 Park Avenue South, New York, NY, United States, 10010

People

▼

Directors & Officers

Name Title Year Born
Mr. Jesse Shefferman Co-founder, CEO, President & Director 1972
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Co-Founder, Chief R&D Officer 1981
Mr. Patrick Fabbio M.B.A. Chief Financial Officer 1968
Ms. Hannah Fry VP, Principal Accounting Officer & Controller 1991
Ms. Justine O'Malley Senior Vice President of Investor Relations & Corporate Affairs NA
Ms. Mary J. Grendell J.D. General Counsel & Corporate Secretary NA
Dr. Shane Williams Ph.D. Chief People Officer NA
Mr. William Conkling Chief Commercial Officer 1971
Carla Beckham M.D., Ph.D. Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist NA
Dr. Neal D. Shore F.A.C.S., M.D. Medical Director of START Carolinas/ Carolina Urologic Research Center NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 08, 2026 Jacqueline Zummo N/A Sale 1.13K $5.40 $6.12K
Apr 01, 2026 Jacqueline Zummo N/A Sale 22.60K $5.26 $118.87K

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 5.21M Mar 31, 2026 8.81% $0.01 1.27%
BlackRock Inc 3.39M Mar 31, 2026 5.74% $0.00 40.94%
Millennium Management LLC 3.10M Jun 30, 2026 5.25% $0.00 9.54%
Velan Capital Investment Management LP 2.84M Jun 30, 2026 4.81% $6.62 0.35%
Blackstone Inc 2.27M Mar 31, 2026 3.83% $0.05 18.63%
Vanguard Capital Management, LLC 2.12M Mar 31, 2026 3.59% $0.00 0.00%
Sio Capital Management, LLC 1.92M Jun 30, 2026 3.25% $1.21 -2.44%
Integral Health Asset Management, LLC 1.50M Jun 30, 2026 2.54% $0.23 -14.29%
UBS Group AG 1.40M Mar 31, 2026 2.37% $0.00 15.37%
5AM Venture Management, LLC 1.37M Jun 30, 2026 2.32% $1.82 0.00%
Citadel Advisors Llc 1.23M Jun 30, 2026 2.09% $0.00 15.33%
Geode Capital Management, LLC 1.18M Mar 31, 2026 1.99% $0.00 44.05%
Point72 Asset Management, L.P. 1.15M Mar 31, 2026 1.95% $0.01 4,001.16%
State Street Corp 1.01M Mar 31, 2026 1.70% $0.00 76.07%
Baker Bros Advisors LP 971.61K Mar 31, 2026 1.64% $0.03 0.00%
ADAR1 Capital Management LLC 940.51K Mar 31, 2026 1.59% $0.29 -17.27%
Bank of America Corp 925.92K Mar 31, 2026 1.57% $0.00 86.71%
J. Goldman & Co LP 856.25K Mar 31, 2026 1.45% $0.13 0.00%
Dimensional Fund Advisors, Inc. 683.23K Jun 30, 2026 1.16% $0.00 28.60%
Morgan Stanley - Brokerage Accounts 556.97K Mar 31, 2026 0.94% $0.00 217.67%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.66M 2.81% ▲ 0.00% Jul 31, 2026
2 iShares Russell 2000 ETF 1.34M 2.27% ▼ 0.57% Aug 31, 2026
3 Columbia Small Cap Value Discv A 758.07K 1.28% ▲ 0.00% Jul 31, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 586.97K 0.99% ▲ 0.00% Jul 31, 2026
5 Fidelity Small Cap Index 567.51K 0.96% ▲ 9.29% Jun 30, 2026
6 iShares Russell 2000 Value ETF 470.30K 0.80% ▼ 0.23% Aug 31, 2026
7 Russell 2000 Index Non-Lendable Fund 337.79K 0.57% ▼ 0.16% Jun 30, 2026
8 Russell 2000 Equity Index Fund B 337.79K 0.57% ▼ 0.16% Jun 30, 2026
9 State St Russell Sm/Mid Cp® Indx SL Cl I 299.50K 0.51% ▼ 0.83% Aug 31, 2026
10 Vanguard Russell 2000 ETF 293.95K 0.50% ▼ 2.31% Jul 31, 2026

Financial Highlights

▼
Market Cap: $225.74M
EBITDA: $-76.45M
Book Value: $2.73
Earnings/Share: $-1.36
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -28.82%
ROE (TTM): -45.80%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $86.00M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 59.10M
Shares Float: 54.88M
% Insiders: 2.30%
% Institutions: 78.38%
Short % Float: 7.63%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-362.00K
Gross Profit
subtotal
$-362.00K
SG&A
adjust
$-21.92M
R&D
adjust
$-42.63M
Operating Income
subtotal
$-64.55M
Other / Non-Operating Items
adjust
$7.11M
Net Income
subtotal
$-57.44M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TARA.US!